-+ 0.00%
-+ 0.00%
-+ 0.00%

Windtree Therapeutics Plans Interim Analysis Results For Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study For July 2025

Benzinga·05/22/2025 12:17:46
Listen to the news

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program